Mundipharma, Novartis to distribute pain medicine in SE Asia
International healthcare organizations, Novartis and Mundipharma, have signed an agreement for the marketing, sales and distribution of wellknown pain medicine brands Voltaren (diclofenac sodium) and Cataflam (diclofenac potassium) in Malaysia, Thailand, and the Philippines. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain, swelling (inflammation), and joint stiffness caused by arthritis. It is available as a tablet, injectable and liquid capsule.
According to Novartis, the company’s commitment to enhance healthcare providers and institutions’ access to effective medicines will be complemented by Mundipharma’s core strengths in anesthesia and surgicals in Southeast Asia. Novartis will retain all international development responsibility, as well as clinical development activities. The company will also continue to manufacture and supply Voltaren and Cataflam for commercial use.